December 13, 2022
December 13, 2022 - ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company
dedicated to manufacturing, marketing and developing
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
International Medical Insurance
December 13, 2022
December 13, 2022 – Idacio (adalimumab-aacf), a tumor necrosis factor (TNF) blocker biosimilar to Humira, has been approved by the FDA for the treatment of rheumatoid arthritis
December 12, 2022
December 12, 2022 – The FDA has granted accelerated approval to Mirati Therapeutics’ Krazati
(adagrasib)
November 18, 2022
November 18, 2022 - Jazz Pharmaceuticals plc announced the FDA approval of a supplemental Biologics
License Application
July 19, 2022
July 19, 2022 – Incyte's OpzeluraTM (ruxolitinib) cream has been approved for the topical treatment of nonsegmental vitiligo in patients who are at least 12 years old.
July 15, 2022
July 15, 2022 – ZonisadeTM (zonisamide oral suspension) has received FDA approval to provide adjunctive therapy for the treatment of partial onset seizures in patients
July 14, 2022
July 14, 2022 – Pfizer’s Xalkori® (crizotinib) has received a new indication to treat unresectable, recurrent,
or refractory ALK-positive inflammatory yofibroblastic
July 14, 2022
July 14, 2022 – Diacomit® (stiripentol) is now indicated for use with clobazam to treat seizures associated with Dravet syndrome in patients at least six months of age and